Biotech & pharma press releases — Press Release Database

AI · Healthcare

Global Digital Biomarkers Market Size, Share, Competitive Landscape, and Forecast - 2033 | AI and Remote Monitoring Drive 13.80% CAGR Toward USD 18.1 Billion

Digital biomarkers can reduce clinical trial costs, improve compliance and outcomes, while remote monitoring lowers hospital readmissions and supports personalized care Digital biomarkers can reduce clinical trial costs, improve compliance and outcomes, while remote monitoring lowers hospital readmissions and supports personalized care

Oct 14 · 09:04GlobeNewswire

Healthcare · Biotech & pharma

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)

Oct 14 · 08:30GlobeNewswire

Biotech & pharma

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

SAN DIEGO, Oct. 14, 2026 -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The...

Oct 14 · 08:07PR Newswire

Healthcare · Biotech & pharma

Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets

Tokyo, Japan and Cambridge, UK, 14 October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma Japan Co., Ltd. (“Nxera Pharma Japan”), has entered into an exclusive license, supply and commercialization agreement (the “Agreement”) with Taiwan-headquartered Synmosa Biopharma Corporation (“Synmosa”) for QUVIVIQ® (daridorexant), a treatment for insomnia, in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand (the “Territory”).

Oct 14 · 07:54GlobeNewswire

Biotech & pharma

MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch

Multi-site program demonstrates threefold increase in rehabilitation training dose, with 84% delivered independently and significant improvements across functional measures GENEVA, Oct. 14, 2026 -- MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision...

Oct 14 · 05:37PR Newswire

Finance · Biotech & pharma

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be...

Oct 14 · 05:00PR Newswire

Finance · Biotech & pharma

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 13, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November...

Oct 13 · 23:39PR Newswire

Healthcare · Biotech & pharma

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --

Oct 13 · 23:30GlobeNewswire

Healthcare · Biotech & pharma

Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate

Orum announced that the first patient has been dosed in a Phase 1 clinical trial evaluating ORM-1153, the Company’s investigational CD123-GSPT1 DAC.

Oct 13 · 23:00GlobeNewswire

Finance · Biotech & pharma

SEC Qualifies GOA Therapeutics’ Public Offering to Sell Up to $300 Million in Stock; Set for Launch October 15

Financing strategy is designed to advance GOA26, a first-in-class drug candidate for the treatment of acute alcohol intoxication and poisoning Financing strategy is designed to advance GOA26, a first-in-class drug candidate for the treatment of acute alcohol intoxication and poisoning

Oct 13 · 22:53GlobeNewswire

Finance · Biotech & pharma

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

MORRISVILLE, N.C., Oct. 13, 2026 -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.

Oct 13 · 21:44GlobeNewswire

Finance · Biotech & pharma

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 13, 2026 -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Oct 13 · 21:08GlobeNewswire